Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Gene Editing Market Size Worth USD 15.79 Billion By 2027 | CAGR of 17.2%: Emergen Research

This image opens in the lightbox

News provided by

Emergen Research

29 Sep, 2020, 13:00 GMT

Share this article

Share toX

Share this article

Share toX

- The growth of the market is attributed to rising government initiatives across major nations and expanding application areas of genomics

- Market Size – USD 4.44 Billion in 2019, Market Growth - CAGR of 17.2%, Market Trends – Exhaustive usage of genome editing in personalized medicine

VANCOUVER, B.C., Sept. 29, 2020 /PRNewswire/ -- The Global Gene Editing Market is projected to reach USD 15.79 billion by 2027, according to a recent report by Emergen Research. The use of the technology for malady wipeout through direct correction of disturbances in traditional physiology, engineering the immunologic response, and alteration of microorganism targets within the host, which is anticipated to drive the market with substantial opportunities.

In order to improve current treatment choices, it is very important to sanction piece of editing technologies to capture significant revenue share. Improved effectualness, reduced aspect effects, which therefore brings the potential cure for specific diseases. These are often attributed to induce growth within the coming years.

Moreover, technological advancements with regard to the event of novel vectors for delivery is anticipated to fuel market growth in the coming years. Rising competition amongst the operating entities to realize a bigger share of revenue will additionally contribute to the projected growth. These firms leverage business collaborations for the acceleration of heterogeneous product pipelines.

Request free sample of this research report at: https://www.emergenresearch.com/request-sample/132

Key Highlights From The Report

  • CRISPR accounted for the biggest share of the market because of a large variety of benefits like the convenience of custom-made choice specific to the patient's mutations for the malady like mucoviscidosis, government initiatives for the event of drug, devices, and vaccines, and investment by market players. For example, in October 2017, Thermo Fisher Scientific and Synthego collaborated to manufacture and distribute artificial guide polymer products for CRISPR order engineering. Moreover, CRISPR is simple to use, works with high outturn, and reasonable technology.
  • Recent developments across order piece of writing technologies have resulted in the creation of next-generation nucleases that have higher levels of accuracy once correcting genetic mutations and defects. The categories beneath the order piece of writing technologies ar the four broad families of nucleases: ZFNs, TALENs, CRISPR/Cas9, and Meganucleases.
  • In June 2019, Vertex Pharmaceuticals acquired Exonics Therapeutics in order to expand medical specialty in gene editing. Exonics has its SingleCut CRISPR sequence piece of technology to develop treatments through repairing mutations that cause different genetic fasciculus diseases with important unmet desires. Hence, the acquisition helped Vertex develop new treatments against rare diseases.
  • Key participants embrace Cibus, Recombinetics, Inc, Merck KGaA, Sangamo, exactitude Biosciences, and Editas medication, among others.
  • North America holds the biggest share of the market and is anticipated to keep its position intact throughout the forecast period. This can be attributed to the native presence of major market players, early adoption of latest technology of sequential piece of editing, and better awareness regarding edges related to sequence piece of writing. Moreover, high government funding and investments by market players for analysis and development activities on genetic modification additionally boost the market. The market across the Asia Pacific region is likely to grow at a steady rate because of the slow adoption of technology and an unorganized regulative atmosphere across countries.

To get leading market solutions, visit the link below: https://www.emergenresearch.com/industry-report/gene-editing-market

For the purpose of this report, Emergen Research has segmented the Global Gene Editing Market on the basis of technology, end user, application, and region:

Technology Outlook (Revenue, USD Billion; 2017-2027)

  • (CRISPR)/Cas9
  • TALENS/MegaTALs
  • ZFN
  • ANTISENSE
  • Other Technologies

Application Outlook (Revenue, USD Billion; 2017-2027)

  • Cell Line Engineering
  • Animal Genetic Engineering
  • Plant Genetic Engineering
  • Diagnostic Applications
  • Drug Discovery and Development

End User Outlook (Revenue, USD Billion; 2017-2027)

  • Biotechnology and Pharmaceutical Companies
  • Academic and Government Research Institutes
  • Contract Research Organizations (CROs)

Regional Outlook (Revenue: USD Billion; 2017-2027)

  • North America
  1. U.S.
  2. Canada
  3. Mexico
  • Europe
  1. U.K.
  2. Germany
  3. France
  4. Benelux
  5. Rest of Europe
  • Asia Pacific
  1. China
  2. Japan
  3. South Korea
  4. Rest of APAC
  • Latin America
  1. Brazil
  2. Rest of LATAM
  • Middle East & Africa
  1. Saudi Arabia
  2. UAE
  3. Rest of MEA

Find more similar research insights by Emergen Research:

Cell-Free DNA Market By Type (Cell-free fetal DNA (NIPT), Circulating tumor DNA, Donor-derived cell-free DNA), By Technology (MPSS, t-MPS, SNP, Others), Application (Transplantation, Gynecology, Oncology), By Region Forecasts to 2027

Interventional Cardiology Market By Product (Catheters, Angioplasty Balloons, Plaque Modification Devices, Angioplasty Stents), By End Users (Cardiac Catheterization labs, Hospitals, Ambulatory surgical centers), Forecasts to 2027

Synthetic Blood Substitutes Market By Source, By Type (Hemoglobin-Based Oxygen Carriers (HBOCs), Perfluorocarbon (PFCs)), By Application (Cardiovascular Diseases, Anemia, Malignant Neoplasm, Injuries and Trauma, Neonatal Conditions, Maternal Conditions, Organ Transplant), By End-Use, Forecasts to 2027

Biophotonics Market By Technology (In-vivo, In-vitro), By Applications (Endoscopy, Spectromolecular, Surface Imaging, Microscopy, Light Therapy, Biosensors) and By End User (Medical Diagnostics, Medical Therapeutics, Test Components) Forecasts to 2027

Cancer Tumor Profiling Market By Technique Type (Genomics, Epigenetics, Metabolomics, Proteomics), By Technology (Immunoassays, In Situ Hybridization, PCR), By Application (Research And Clinical Application), Forecasts to 2027

Craniomaxillofacial Devices Market Analysis, By Product (Cranial Flap Fixation Device, CMF Distraction Device, Drugs), By Material (Metal Based Implants, Bioabsorbable Material), By Application, By End-Use, Forecasts to 2027

About Emergen Research 

At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

With market-leading insights and an in-depth understanding of leading and niche technologies, our solutions address the most pertinent questions for your business needs. A major technological shift has been witnessed towards creating a 'Circular Economy,' fuelled by factors, such as the increased adoption of bio-based materials, along with other methods for achieving carbon neutrality. We are conversant in technologies, viz., Artificial Intelligence (AI), Augmented Reality (AR), Virtual Reality (VR), Robotic Process Automation (RPA), Smart Manufacturing, Internet of Things (IoT), Big Data Analytics, Machine learning, Nanotechnology, Edge Computing, Blockchain Technology, Cloud Computing, Vehicle Electrification, Advanced Maintenance Analytics, and Predictive Maintenance, among other prevalent and emergent technologies.

Contact Us:

Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Read full Press Release at : https://www.emergenresearch.com/press-release/global-gene-editing-market

Logo: https://mma.prnewswire.com/media/1252126/Emergen_Research_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.